We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Non-Invasive Skin Swab Samples Enough to Quickly Detect COVID-19, Finds New Study

By LabMedica International staff writers
Posted on 17 Mar 2021
Illustration
Illustration
Non-invasive skin swab samples are enough to quickly detect COVID-19, according to findings of a new study.

In the study, researchers at the University of Surrey (Guildford, Surrey, UK), collected sebum samples from 67 hospitalized patients - 30 who had tested positive for COVID-19 and 37 who had tested negative. The samples were collected by gently swabbing a skin area rich in sebum - an oily, waxy substance produced by the body's sebaceous glands - such as the face, neck or back. The researchers analyzed the samples by using liquid chromatography mass spectrometry and a statistical modeling technique called Partial Least Squares - Discriminant Analysis to differentiate between the COVID-19 positive and negative samples.

The team then found that patients with a positive COVID-19 test had lower lipid levels - or dyslipidemia - than their counterparts with a negative test. The accuracy of the study’s results increased further when medication and additional health conditions were controlled.

"Unfortunately, the specter of future pandemics is firmly on the top of the agenda for the scientific community. Our study suggests that we may be able to use non-invasive means to test for diseases such as COVID-19 in the future - a development which I am sure will be welcomed by all," said Dr. Melanie Bailey, co-author of the study from the University of Surrey.

"COVID-19 damages many areas of metabolism. In this work, we show that the skin lipidome can be added to the list, which could have implications for the skin’s barrier function, as well as being a detectable symptom of the disease itself," added Matt Spick, co-author of the study from the University of Surrey.

"Investigating new methods of diagnosis and surveillance in a new disease such as COVID-19 that has had such a devastating effect on the world is vital. Sebum sampling is a simple, non-invasive method that shows promise for both diagnostics and monitoring of the disease in both a healthcare and a non-healthcare setting," noted Dr. George Evetts, Consultant in Anesthesia & Intensive Care Medicine at Frimley Park Hospital.

Related Links:
University of Surrey

Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]

Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more